Lantern Pharma
LTRN
39 hedge funds and large institutions have $6.01M invested in Lantern Pharma in 2024 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 6 closing their positions.
1,088% more call options, than puts
Call options by funds: $309K | Put options by funds: $26K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
15% more funds holding
Funds holding: 34 → 39 (+5)
1.63% more ownership
Funds ownership: 10.32% → 11.95% (+1.6%)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
38% less capital invested
Capital invested by funds: $9.75M → $6.01M (-$3.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Davenport & Co
Richmond,
Virginia
|
+$384K |
| 2 |
Two Sigma Investments
New York
|
+$209K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$204K |
| 4 |
BlackRock
New York
|
+$121K |
| 5 |
Renaissance Technologies
New York
|
+$96.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFA
Pathway Financial Advisors
South Burlington,
Vermont
|
-$220K |
| 2 |
Jane Street
New York
|
-$150K |
| 3 |
TAM
Tucker Asset Management
Littleton,
Colorado
|
-$101K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$20.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.1K |
LTRN Hedge Fund Activity: Q2 2024 in Review
39 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q2 2024, worth a combined $6.01M — down 38% from $9.75M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LTRN positions and 6 closed out — a net gain of 5 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Davenport & Co, opening a new position worth an estimated $384K. The largest seller was Pathway Financial Advisors, exiting entirely with an estimated $220K sold.
- 39 institutional investors held Lantern Pharma (LTRN) as of Q2 2024, up from 34 in Q1 2024.
- Funds reported $6.01M of Lantern Pharma stock for Q2 2024, down 38% quarter-over-quarter.
- 11 funds opened new Lantern Pharma positions in Q2 2024 and 6 closed out, a net change of +5 holders.
- The largest Lantern Pharma buyer in Q2 2024 was Davenport & Co, an estimated $384K added.
- The largest Lantern Pharma seller in Q2 2024 was Pathway Financial Advisors, an estimated $220K sold.
Based on aggregated 13F filings for Q2 2024.